Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (37)

2024

  1. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

  2. Feasibility and Short-Term Outcomes in Liver-First Approach: A Spanish Snapshot Study (the RENACI Project)

    Cancers, Vol. 16, Núm. 9

  3. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663

  4. Textbook outcomes in the liver-first approach for colorectal liver metastases: prospective multicentre analysis

    BJS Open, Vol. 8, Núm. 1

2023

  1. Correction: ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia (Intensive Care Medicine, (2023), 49, 6, (615-632), 10.1007/s00134-023-07033-8)

    Intensive Care Medicine

  2. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia

    Intensive Care Medicine, Vol. 49, Núm. 6, pp. 615-632

  3. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia

    European Respiratory Journal, Vol. 61, Núm. 4

  4. Residual pulmonary infiltrates, symptoms and diffusion impairment at 1-year after severe COVID-19 infection have different associated factors

    Journal of Internal Medicine, Vol. 294, Núm. 1, pp. 69-82

2021

  1. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  2. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score

    British Journal of Surgery, Vol. 19, Núm. 4

2020

  1. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer

    Clinical and Translational Oncology, Vol. 22, Núm. 1, pp. 21-36

2015

  1. The surgical experience of general surgery residents: An analysis of the applicability of the specialty program in General and Digestive Surgery

    Cirugia Espanola, Vol. 93, Núm. 3, pp. 152-158

2014

  1. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants

    International Journal of Cancer, Vol. 134, Núm. 9, pp. 2088-2097

2012

  1. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study

    Oncologist, Vol. 17, Núm. 7, pp. 947-955

  2. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  3. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  4. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study

    Oncologist, Vol. 17, Núm. 3, pp. 339-345

  5. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2010

  1. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

    Breast Cancer Research and Treatment, Vol. 119, Núm. 1, pp. 221-232

2009

  1. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

    Annals of Oncology, Vol. 20, Núm. 2, pp. 251-257